Lilian joined Catamaran as Vice President, Preclinical Development and Biomarkers, in April 2022. Prior to Catamaran, Lilian was Senior Director, Preclinical Safety and Translational Biomarkers at Dyne Therapeutics, where she led the development of biomarker and bioanalytical strategies to support the development of therapies for patients with severe muscle diseases. Before her time at Dyne, Lilian was Director of Translational Sciences at bluebird bio where she formulated strategies for post-treatment monitoring of patients treated with CAR-T cell therapy and stem cell-based gene therapy products, overseeing analysis of PK & PD samples from clinical trials across the entire portfolio. Prior to bluebird bio, she was Associate Director at AstraZeneca in the department of drug metabolism and pharmacokinetics, where she led a multidisciplinary team conducting in vitro metabolism, biotransformation, and drug interaction studies supporting multiple therapeutic areas. Lilian started her pharmaceutical career in the department of Drug Safety and Metabolism at Wyeth Pharmaceuticals. Lilian conducted her postdoctoral training at the University of Dundee in Scotland. She holds a PhD in Molecular Genetics from Staffordshire University (UK), an MS in Clinical Biochemistry from Leeds University (UK) and a BS in Biochemistry and Biology from Keele University (UK).
Mike joined Catamaran as Senior Vice President, Corporate Strategy and New Product Planning in February 2022. He has extensive experience leading product planning and portfolio strategy in the cell therapy and immuno-oncology areas. Prior to Catamaran, Mike was Vice President, Medicine Commercialization Leader for Cell and Gene Therapies at GlaxoSmithKline (GSK). In this role he was responsible for planning the global launch of letetresgene autoleucel (NY-ESO-1 TCR-T cell therapy), operational design and implementation of GSK’s cell therapy capabilities, and for cell therapy portfolio strategy. He also made major contributions to GSK’s reentry into oncology by playing a leading role in the company’s $5B acquisition of Tesaro in 2019. Prior to this, he held roles of increasing responsibility at GSK in new product planning and business development across a range of disease areas. Mike began his career as a strategy consultant at LEK Consulting. Mike holds a PhD in Biomedical Engineering from the University of Pennsylvania and a BSE in Bioengineering from Tulane University.
Tara joined Catamaran as Vice President, Human Resources and Organizational Effectiveness in November 2021. She brings more than 20 years of experience in all aspects of human resources, implementing organizational strategies to drive business results and support high-growth companies. As a global human resources leader, Tara has broad experience and proven expertise in building cultures that attract, retain and develop world class talent. Prior to joining Catamaran, Tara led human resources at Chiasma, Inc., where she oversaw all organizational development and HR initiatives, including talent acquisition, leadership development, and employee retention strategies, as the company transitioned to a commercial biotech organization. During her tenure with Vertex Pharmaceuticals and Biogen, Tara held leadership roles in many aspects of human resources, including talent acquisition, learning and development, employee engagement, and diversity and inclusion. Tara holds a BA in Psychology from Boston University and an MBA from Simmons Graduate School of Management.
Alvin joined Catamaran as President and CEO in February 2021. He is an experienced physician and biopharma executive with a track record of building and leading companies that develop therapeutics addressing significant unmet medical needs. Most recently, Alvin was CEO of Disarm Therapeutics, a private neuroscience company that was acquired by Eli Lilly in 2020. Prior to Disarm, Alvin was CEO of Enzyvant Therapeutics, a company developing cell/tissue-based regenerative medicines for rare diseases. He previously held senior leadership roles at Retrophin and Pfizer, where he was the Chief Operating Officer of the Pfizer Rare Disease Research Unit. Alvin began his industry career as a strategy consultant at McKinsey & Co. and LEK Consulting. He holds an MD from the University of Alabama, an MBA from the Kellogg School of Management, and a BA from Vanderbilt University. Alvin completed his residency training in internal medicine at the Massachusetts General Hospital.
Dave joined Catamaran as Vice President, Finance in June 2021. He has worked at growing biotech companies and built a track record of progressive operational finance experience. Most recently, Dave was Senior Director, Finance at Akebia Therapeutics, a publicly-traded, fully integrated biopharmaceutical company that develops and commercializes renal therapeutics. Prior to Akebia, he served as the Senior Director of Finance & Accounting and Controller at Keryx Biopharmaceuticals. While at Keryx, Dave was a key finance partner in the company’s strategic merger with Akebia. He began his career at PwC in the assurance practice, supporting clients in the life sciences and healthcare industries. Dave holds an MS in Accounting and a BS in Finance and Accounting from the Carroll School of Management at Boston College and is a certified public accountant in the Commonwealth of Massachusetts.
Dominic joined Catamaran as Senior Director, In Vivo Pharmacology in March 2021. Prior to joining Catamaran, Dominic led the in vivo pharmacology teams at Cobalt Biomedicine and subsequently Sana Biotechnology. In those roles, Dominic focused on proof of concept and candidate selection studies for gene and engineered cell therapeutic approaches in a variety of disease indications including oncology, rare monogenic hepatic disorders and acute liver failure. Prior to his gene/cell therapy experience, Dominic managed external preclinical studies for Catabasis Pharmaceuticals with a specific focus on NASH, Duchenne’s Muscular Dystrophy, and Cystic Fibrosis. Dominic began his post academic career at LeukoSite where he focused on integrins and chemokine receptors as therapeutic targets to modulate homing and recruitment of specific leukocyte subsets to sites of inflammation involved in the pathogenesis of multiple disease indications. He conducted his postdoctoral training in the Immunobiology Section at Yale University where he studied mechanisms of peripheral anergy of T cells. Dominic holds a PhD in Immunology from Tufts University, and he earned an MS in Microbiology and an AB in Chemistry from Rutgers University.
Joe joined Catamaran as Vice President, Technical Operations and Manufacturing, in August 2021. He brings more than twenty-five years of experience in cell therapy development and GMP manufacturing of cell and gene therapies. Prior to Catamaran, Joe served as Senior Director, Manufacturing at City of Hope’s Center for Biomedicine and Genetics where he led viral vector and cell therapy process development and GMP manufacturing for oncology and regenerative medicine projects for City of Hope clinical trials and external clients. Before his role at City of Hope, he worked at Stanford’s Cardiovascular Institute as Assistant Director of Translational Research, working to bring stem cell-derived therapies for heart failure to the clinic. Joe began his career in biotechnology at Geron Corporation, where he headed up basic research into pluripotent stem cell-derived therapies for diseases ranging from spinal cord injury to diabetes to heart failure. Joe performed his postdoctoral research at UCSF in early embryological development. He holds a PhD in Cell and Developmental Biology from Harvard and a BS in Biology from University of Pennsylvania.
Scott joined Catamaran as CFO in April 2021. He is an experienced biopharma executive with a strong track record of financing, building and strategically positioning private and public companies for growth and value creation. Most recently, Scott was CFO of Disarm Therapeutics, a private neuroscience company that was acquired by Eli Lilly in 2020 for up to $1.36B in upfront and milestones payments. Prior to Disarm, Scott was CFO of Kiadis Pharma N.V., a Netherlands based NK cell therapy company. Previously Scott was Chief Financial Officer at Keryx Biopharmaceuticals until its merger with Akebia Therapeutics. He also held served as Senior Vice President of Finance and Investor Relations at AMAG Pharmaceuticals. Scott began his career at Ernst & Young in both the Assurance and Transaction Advisory Services practices. He holds an MS/MBA from Northeastern University and a BA in History from Middlebury College.
Chris joined Catamaran as Chief Medical Officer in November 2020. He brings more than two decades of clinical and laboratory experience in oncology. Prior to Catamaran, Chris was Chief Medical Officer of Rubius Therapeutics. Previously, Chris was a Senior Vice President and Head of the Cancer Epigenetics Discovery Performance Unit at GlaxoSmithKline. He was responsible for the overall strategy, as well as the identification and validation of new targets and advancing novel therapies through clinical proof of concept. Under his leadership the group brought four compounds into clinical development. While at GSK, Chris also led the clinical development of Votrient® (pazopanib). Prior to GSK, he led the clinical development of MK-4827, which became Tesaro’s Zejula®. Prior to Merck, Chris led a laboratory focus on signal transduction at Harvard Medical School and the Beth Israel Deaconess Medical Center for 14 years. He is board certified in medical oncology. Chris holds a BS from Stanford University and MD and PhD (pharmacology) degrees from the University of Southern California. He completed a residency in internal medicine at UT Southwestern, his hematology/oncology fellowship at Massachusetts General Hospital, and a post-doctoral fellowship in Lewis Cantley’s laboratory.
Vipin joined Catamaran as Chief Scientific Officer in March 2020. Along with his deep expertise in researching and developing cell therapies for cancer, Vipin has over two decades of experience in the biotech and pharmaceutical industry. Most recently, he co-founded and led Discovery Research at Obsidian Therapeutics. Vipin’s work at Obsidian led to the development of Obsidian’s cytoDRive platform, which broadened the therapeutic reach of cell and gene therapies. Prior to Obsidian, Vipin was a member of the founding team and Head of Biology at Serien (formerly Raze) Therapeutics and an Entrepreneur in Residence at Atlas Venture. At Raze, Vipin’s research was focused on discovering novel anticancer agents by targeting unique vulnerabilities of rapidly growing tumors. Earlier in his career, Vipin spent more than a decade working in the pharmaceutical industry at GSK, Pfizer, and Wyeth, where his research spanned novel small molecule, peptide, nucleic acid, and protein therapeutics across a wide range of therapeutic areas. Vipin holds a PhD in biochemistry from Brandeis University and an MBA from Yale School of Management.